Key result
ABCA1 variant testing confirms Tangier disease diagnosis and aids cardiovascular risk assessment.
Why the study?
The clinical value and limitations of genetic testing for diagnosing and advising on cardiovascular risk in rare Tangier disease and related familial HDL deficiency caused by ABCA1 variants are not well defined.
Case Report (n=1)
Illustrates the role of genetic testing in diagnosing and assessing cardiovascular risk in rare lipid disorders like Tangier disease.
Background: Dysfunctional variants in the ATP-binding cassette transporter A1 (ABCA1) gene cause the very rare and autosomal recessive Tangier disease.Classical clinical features include orange-coloured pharyngeal tonsils, hepatosplenomegaly and sensory neuropathy.Affected individuals have low levels of both HDL-cholesterol (HDL; <1 to 13% of normal) and apolipoprotein A1 (ApoA1).However, the autosomal dominant familial HDL deficiency (FHD) can also be caused by variant(s) in the ABCA1 gene and also presents with low levels of HDL (30 to 83% of normal) and ApoA1.The typical clinical presentation is of yellow/ brown xanthomata.Both conditions are associated with an increased risk of cardiovascular disease; with Tangier disease considered to carry a more significant risk.The conditions are thought to be related, where one ABCA1 variant is associated with FHD and two ABCA1 variants with Tangier disease. Case history: Adult female 65-year-old patient reviewed in the Lipid clinic. Steps to confirming a diagnosis;This article is part of a special issue entitled: Heart UK 2026
No takes yet. Share an insight, caveat, or question.
Baxter et al. (2026) conducted a case report in Tangier Disease (n=1). Genetic testing for ABCA1 gene variants was evaluated. Genetic testing for ABCA1 variants was evaluated in a 65-year-old female patient to confirm a diagnosis of Tangier disease and assess cardiovascular risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: